EI
SCLN

EAM Investors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

EAM Investors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-117,078
Closed -$1.03M – 428
2014
Q4 		$1.03M Buy
+117,078
New +$948K 0.14% 286

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

EAM Investors's SCLN Position: Q1 2015 in Review

EAM Investors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2015, closing a stake of 117,078 shares — an estimated $1.03M sold.

EAM Investors first reported a position in SCLN in Q4 2014 and held it in 1 quarter. The position peaked at $1.03M in Q4 2014. 130 funds tracked by Wall St. Rank hold SCLN as of Q1 2015.

  • EAM Investors reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • EAM Investors sold 117,078 Sciclone Pharmaceuticals Inc shares in Q1 2015, an estimated $1.03M.
  • EAM Investors first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 1 quarter.
  • EAM Investors's Sciclone Pharmaceuticals Inc position peaked at $1.03M in Q4 2014.
  • 130 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2015.

Based on EAM Investors's 13F filing for Q1 2015, filed 7 May 2015.